Mounjaro Scores Yet Another Win: Why Eli Lilly Is Still a Buy

The drugmaker looks unstoppable.To paraphrase a Shakespeare quote, bad news and misfortune tend to come in groups. But that may also apply to good news. Just ask Eli Lilly (LLY -0.15%), a pharmaceutical company that has been flying on all cylinders. The drugmaker continues to impress investors with exceptional financial results, impressive regulatory wins, and exciting clinical progress.Much of the company's recent success has to do with tirzepatide, a medicine for diabetes (marketed as Mounjaro) and for ob ...